Plot No.367, Abhey Pur, Industrial Area Phase-1, Panchkula, Haryana 134109
Don't miss out on this limited-time offer to join our successful PCD Pharma network. Fill in your details below and our team will get in touch with you to discuss the best franchise opportunities tailored to your needs.
Rosuvastatin 20 mg + Ezetimibe 10 mg tablet
Therapeutic Category
Cardiology, Cardiovascular
Dosage Form
Tablet
Packaging Type
Alu Alu
Packaging
10*10
Price
₹249/-
High-resolution images and Product visuals
Product overview and usage information
Detailed information and research documents
Rosuvastatin 20 mg + Ezetimibe 10 mg Tablet is a dual-action lipid-lowering formulation that combines a statin with a cholesterol absorption inhibitor. Rosuvastatin, an HMG-CoA reductase inhibitor, works by reducing cholesterol synthesis in the liver, while Ezetimibe selectively inhibits the absorption of cholesterol from the small intestine. Together, they provide a synergistic effect to effectively lower LDL cholesterol and total cholesterol levels, making it suitable for patients who require intensive lipid control or have not achieved goals with statin monotherapy. This combination supports cardiovascular risk reduction in patients with hyperlipidemia or mixed dyslipidemia.
Common side effects may include headache, muscle pain, fatigue, and abdominal discomfort. In rare cases, patients may experience liver enzyme elevation, rhabdomyolysis, or hypersensitivity reactions. Periodic monitoring of liver function and creatine kinase levels is advised, especially in patients with predisposing factors for myopathy.
Indicated for the treatment of primary hyperlipidemia or mixed dyslipidemia in adults as an adjunct to diet. It is particularly beneficial for patients requiring additional LDL cholesterol reduction when lifestyle modifications and statin therapy alone are insufficient. The combination is also used in the management of homozygous familial hypercholesterolemia and to lower the risk of cardiovascular events in high-risk patients.
To be used under the supervision of a registered medical practitioner. Not recommended in patients with active liver disease or unexplained persistent elevations in hepatic transaminases. Caution should be exercised in patients with renal impairment or those on other lipid-lowering agents. Avoid use during pregnancy and lactation.
Store at a temperature below 30°C, away from moisture and direct sunlight. Keep out of reach of children.
Composition : Rosuvastatin 10 mg tablet
Composition : Rosuvastatin (20mg) tablet
Composition : Rosuvastatin 40 mg tablet
Composition : Rosuvastatin 10 mg + fenofibrate 160 mg tablet
Composition : Rosuvastatin 20 mg + fenofibrate 160 mg tablet
Composition : Rosuvastatin 5mg + fenofibrate 160 mg tablet
Composition : Rosuvastatin 10 mg + Aspirin 75 mg tablet
Composition : Atorvastatin Calcium I.P. 80mg Tablets
Composition : Atorvastatin Calcium I.P. 20mg Tablets
This catalog is a digital representation of the Cafoli Lifecare portfolio and is intended for use by authorized pharmaceutical distributors and PCD franchise partners.
Rosuvastatin 20 mg + Ezetimibe 10 mg Tablet is a lipid-lowering (anti-hyperlipidemic) combination used for the management of high cholesterol, mixed dyslipidemia, and prevention of cardiovascular diseases such as heart attack and stroke. It combines a statin (Rosuvastatin) that reduces cholesterol production with Ezetimibe that reduces cholesterol absorption, making it a highly effective cardiac care segment product widely prescribed by cardiologists and physicians.
Medical distributors and wholesalers benefit from the high chronic demand in cardiovascular and lifestyle disease management. Cholesterol-lowering therapies are long-term treatments with continuous prescription refills, ensuring stable monthly sales, strong repeat orders, and consistent demand from retail and hospital pharmacies.
Yes, Cafoli Lifecare provides PCD pharma franchise opportunities in the cardiovascular and lipid-lowering segment, including Rosuvastatin + Ezetimibe combinations. We offer monopoly rights, quality manufacturing standards, and consistent supply support to help franchise partners grow in the chronic cardiac therapy market.
Wholesalers and stockists benefit from continuous prescription-driven demand, long-term patient dependency, and strong cardiology market penetration. As cholesterol management is part of lifelong therapy in many patients, this ensures regular consumption, stable turnover, and reliable business growth in the pharma distribution sector.
Medical distributors, stockists, and pharma professionals interested in cardiovascular and lipid-lowering products can contact Cafoli Lifecare for pricing details, monopoly franchise opportunities, and product availability. We provide complete support including marketing materials, product supply, and territory-based business assistance.